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Cerebrospinal ﬂuid (CSF) has been used for biomarker discovery of neurodegenerative diseases in humans since biological
changes in the brain can be seen in this bioﬂuid. Inactivation of A-T-mutated protein (ATM), a multifunctional protein kinase, is
responsibleforA-T,yetbiochemicalstudieshavenotsucceeded inconclusivelyidentifyingthemolecularmechanism(s)underlying
the neurodegeneration seen in A-T patients or the proteins that can be used as biomarkers for neurologic assessment of A-T
or as potential therapeutic targets. In this study, we applied a high-throughput LC/MS-based label-free protein quantiﬁcation
technology to quantitatively characterize the proteins in CSF samples in order to identify diﬀerentially expressed proteins that can
serve as potential biomarker candidates for A-T. Among 204 identiﬁed CSF proteins with high peptide-identiﬁcation conﬁdence,
thirteen showed signiﬁcant protein expression changes. Bioinformatic analysis revealed that these 13 proteins are either involved
in neurodegenerative disorders or cancer. Future molecular and functional characterization of these proteins would provide more
insights into the potential therapeutic targets for the treatment of A-T and the biomarkers that can be used to monitor or predict
A-T diseaseprogression. Clinical validation studies are required before any of these proteins can be developed into clinicallyuseful
biomarkers.
1.Introduction
A-T is a neurodegenerative disease characterized by progres-
sive cerebellar degeneration, immunodeﬁciency, cancer pre-
disposition, premature aging, growth retardation, gonadal
atrophy, high sensitivity to ionizing radiation, and genomic
instability [1–6]. Many studies have suggested that a deﬁ-
ciency in the ability to repair DNA double-strand breaks
( D S B s )i st h em a i nc a u s eo ft h eA - Tp h e n o t y p e[ 7]. A major
breakthrough in understanding the pathophysiology of A-
T came with the identiﬁcation of the defective gene, ATM
(ataxia-telangiectasia mutated), which is mutationally inac-
tivated in individuals with the disease [8]. The identiﬁcation
ofATM has facilitated rapid progress in understanding many
aspects of the molecular basis of this disease.
TheATMproteinisaserine-threonine kinasethat under-
goes autophosphorylation in response to DNA damage
and subsequently initiates a signaling cascade that involves2 International Journal of Proteomics
the phosphorylation of several down-stream substrates,
including p53, p53BP1, Chk2, BRCA1, and TRF2 [7, 9, 10].
Recently, substantial insight has been obtained regarding
the mechanism by which ATM signals to eﬀector proteins
after DNA double-strand breaks have occurred. Although
ATM is an essential factor for sensing and signaling the
repair of DSBs, other factors such as the MRN complex
(Mre11/Rad50/Nbs1) may play an important upstream role
in the activation of ATM [11]. In addition, ATM isa member
of a large protein complex called the BRCA1-associated
genome surveillance complex, suggesting that DNA damage
recognition and signaling also involve other proteins, several
of which are substrates for ATM [12]. A vast amount of
literature has demonstrated the role of ATM in regulating a
damage response pathway that ultimately leads to cell cycle
checkpoint arrest, DNA repair, or apoptosis [13]. Under-
standing this role of ATM has explained the predisposition
of A-T patients to develop immunodeﬁciency and cancer
but has not explained the observed neurodegeneration. A
global quantitative analysis of proteins associated with the
A-T phenotype from A-T patient samples has not yet been
reported but might shed new light on this dilemma.
O n eo ft h eg o a l so fp r o t e o m i c si st om e a s u r ea n d
characterize the protein expression proﬁles in speciﬁc tissues
and bioﬂuids. Even though a tremendous eﬀort has been
made to improve proteomic technologies, there are still
numerouschallengesassociatedwitheventhemostadvanced
technologies when analyzing global protein expression due
to the inherent complexity of clinically relevant biological
samples. These challenges include: (1) the sensitivity of the
instrument and its ability to identify novel proteins, (2) the
need to be moderate to high throughput, (3) the wide range
of protein masses and abundances (dynamic range) that
need to be covered, (4) the ability to quantitatively analyze
protein expression and posttranslational modiﬁcations, and
(5) access to the appropriate tissue and/or bioﬂuid. With
the recent development of a label-free protein quantiﬁcation
technology [14], large-scale and highthroughput analysis of
complex biological samples has become possible which has
overcomesomeofthechallenges inproteomics[15–18].This
unique technology combines a proprietary sample prepara-
tion protocol [19], the LC/MS method, and statistical data
analysis tools to quantitatively analyze proteins from whole
tissue homogenates, cell lysates, or depleted serum/plasma
samples.
In this work, we used cerebrospinal ﬂuid (CSF) samples
from A-T patients and age- and gender-matched unaﬀected
controls to identify and verify potential biomarkers of A-
T. CSF was selected as it has been shown to be a relevant
biological sample to study other neurodegenerative diseases
suchas Alzheimer’s disease (AD),and tostudychanges in the
predominantclinicalphenotypeofA-T(neurodegeneration)
that have not been addressed in previous studies [20–22].
2.Materialsand Methods
2.1. Reagents and Chemicals. Urea, ammonium carbonate,
ammonium bicarbonate, mass-spectrometry grade formic
acid, 2-iodoethanol, triethylphosphine and ProteoPrep spin
cartridges were all purchased from Sigma-Aldrich (St. Louis,
Mo, USA). Modiﬁed trypsin was purchased from Promega
(Madison, Wis, USA). HPLC-grade water and acetonitrile
were from Burdick & Jackson (Muskegon, Mich, USA).
2.2. Human Subjects. We contacted all adults (≥18 years
of age) with A-T followed at the A-T Clinical Center at
Johns Hopkins Medical Center. Eight were willing to have
a lumbar puncture for the purpose of this research. The
diagnosis of A-T was made by the combination of three
observations: (1) characteristic neurologic abnormalities
suchasoculomotorapraxia,bulbardysfunction andpostural
instability, (2) occulocutaneous telangiectasia, and (3) at
least two of the following laboratory abnormalities: elevated
serum alpha-fetoprotein level, absence of ATM on a western
blot, increased rate of X-ray induced chromosomal breakage
in comparison to a control population, and/or mutations in
both alleles of the ATM gene.
Controls were otherwise healthy individuals having a
lumbar puncture performed for a clinical indication (e.g.,
suspected pseudotumor cerebri or evaluation of chronic
headache) and found not tohave another neurologicdisease.
The institutional review board of the Johns Hopkins
Medical Institutions approved the study, and informed
consent was obtained from every subject.
2.3. CSF Samples. The CSF samples were collected at Johns
Hopkins Hospital (Baltimore, Md, USA). Lumbar punctures
were performed by standard clinical technique using local
anesthetic. The ﬁrst 4mL of CSF were used for standard
chemistry and hematologytests. The next 1mL was collected
for proteomic analysis, immediately transported to the
laboratory, and frozen at −80◦C.
The A-T group consisted of eight patients, six women
and two men, ranging in age from 20 to 26 years old
(mean ± S.D., 22.17 ± 2.13 years) (Table 1). As determined
by the Bradford protein assay [23], the total CSF protein
concentration in all samples ranged from 211.5μg/mL to
441.5μg/mL with a mean of 288.5 ± 93μg/mL. The control
group consisted of ﬁve gender- and age-matched healthy
controls. In the controlgroup,the mean CSF proteinconcen-
tration was 200.7 ± 81μg/mL, ranging from 98.9μg/mL to
369.9μg/mL. Aliquots of CSF were stored in polypropylene
tubes at −80◦Cu n t i lu s e .
2.4. Sample Preparation. The two most abundant serum
proteins, albumin,andIgGwereremoved fromtheCSFsam-
ples using ProteoPrep spin columns. Depleted CSF samples
were denatured by 8M urea for 1h with agitation at room
temperature. Chicken lysozyme (0.25μg, used as QA/QC
reagent) and a volatile reduction/alkylation solution (97.5%
acetonitrile, 2% iodoethanol, and 0.5% triethylphosphine)
were added to each sample, and the solutionswere incubated
at37◦Cfor1haccordingtoapreviouslypublishedprocedure
[19]. The samples were dried under vacuum on a speed-
vac. The resulting pellets were redissolved in 100μLo f
100mMammonium bicarbonate(pH8)containing0.4μgofInternational Journal of Proteomics 3
Table 1: Summary of the CSF samples used for the study.
Sample Age Gender Type
Control 1 23 M Pseudotumor cerebri
Control 2 28 M Headaches
Control 3 32 F Pseudotumor cerebri
Control 4 39 F Pseudotumor cerebri
Control 5 44 F Pseudotumor cerebri
A-T 1 21 F A-T patient
A-T 2 21 F A-T patient
A-T 3 26 F A-T patient
A-T 4 20 M A-T patient
A-T 5 22 M A-T patient
A-T 6 23 F A-T patient
A-T 7 20 F A-T patient
A-T 8 22 F A-T patient
modiﬁed trypsin (Promega) and incubated for 4h at 37◦C.
After a second addition of trypsin, the samples were incu-
bated overnight at 37◦C. All samples containing the tryptic
peptides were ﬁltered through a 0.45-μm ﬁlter (Millipore,
Billerica, Mass, USA) to avoid column clogging in LC/MS
analysis.
2.5. LC-MS/MS Analysis. Tryptic peptides (2μg) were ana-
lyzed by a Thermo-Fisher Scientiﬁc LTQ linear ion-trap
quadrupole mass spectrometer interfaced with a nano-
electrospray ion source built in-house. The trapping column
(NanoEase,C18 Column, 18μm × 23.5mm, Waters, Milford,
Mass, USA) and analytical column (nanoACQUITY UPLC
BEH C18 Column, 1.7μm, 100μm × 100mm, Waters) were
used for peptide separation. Solvent A contained 99.9%
HPLC-grade water and 0.1% formic acid, and solvent B
contained 99.9% HPLC-grade acetonitrile and 0.1% of
formic acid. The sample injection orders were randomized.
The peptides were eluted with a linear gradient from 5 to
50% solvent B developed over 150min at a ﬂow rate of
200nL/min, and eﬄuent was electrosprayed into the LTQ
mass spectrometer. The data were collected in “Triple-Play”
mode (MS scan, Zoom scan, and MS/MS scan).
2.6. Protein Identiﬁcation and Quantiﬁcation. Protein data-
base searches against the International Protein Index (IPI)
human database (v3.60) and the NCBI Non-redundant-
homo sapiens database (updated in June 2009) were carried
out by both the SEQUEST (Thermo-Fisher Scientiﬁc,
Waltham, Mass) and X!Tandem (an open-source software
available from the Global Proteome Machine Organization,
http://www.thegpm.org/) database searching algorithms.
Identiﬁed proteins were categorized into two priority groups
based on the quality of the peptide identiﬁcation and the
number of unique peptides identiﬁed [24]. All the proteins
were identiﬁed with at least one best peptide identiﬁed at a
conﬁdence level ≥90% (q-value ≤ 0.1, q-value represents a
false-discovery-rate or FDR which was described previously
[14, 21])orhigher. Proteins were assigned toPriority 1iftwo
or more unique peptides were identiﬁed or Priority 2 if only
a single peptide was identiﬁed. Peptides assigned to proteins
with a conﬁdence level of less than 90% were ﬁltered out
of this study. The estimation of the conﬁdence levels, which
is based on a random forest recursive partition supervised
learning algorithm was described previously [24].
Protein quantiﬁcation was carried out using a propri-
etary protein quantiﬁcation algorithm licensed from Eli Lilly
&Company(Indianapolis,Ind,USA)asdescribedpreviously
[14]. Brieﬂy, once the raw ﬁles were acquired from the
LTQ, all extracted ion chromatograms (XICs) were aligned
by retention time. To be used in the protein quantiﬁcation
procedure, each aligned peak must match the parent ion,
charge state, fragment ions (MS/MS data), and retention
time (within a 1-min window). After alignment, the area-
under-the-curve (AUC) for each individually aligned peak
from each sample was measured, quantile normalized [25],
and compared for relative abundance. All peak intensities
were transformed to a log2 s c a l eb e f o r eq u a n t i l en o r m a l -
ization. Quantile normalization was employed to ensure
that every sample has a peptide intensity histogram of
the same scale, location, and shape. This normalization
removes trends introduced by technical variations includ-
ing sample handling, sample preparation, total protein
diﬀerences, and changes in instrument sensitivity while
running multiple samples [25]. If multiple peptides have
the same protein identiﬁcation, then their quantile normal-
ized log2 intensities were averaged to obtain log2 protein
intensities. The log2 protein intensity is the ﬁnal quantity
that is ﬁt by a separate ANOVA statistical model for each
protein
Log2

Intensity

= Group + Sample

Group

. (1)
Sample(Group) is a random eﬀect. Group eﬀect refers
to the eﬀect caused by the experimental conditions or
treatments being evaluated. Sample eﬀect represents the
random eﬀects from individual biological samples. It also
includes random eﬀects from sample preparation. All of the
injections were randomized, and the same person operated4 International Journal of Proteomics
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Figure 1: LinearDiscriminantAnalysis(LDA) ofdiﬀerentially expressed proteins in A-T. A panel of13 diﬀerentially expressed proteins were
analyzed by LDA (a function of JMP version 8 software). Expression diﬀerences of proenkephalin-A (P01210), isoform 1 of extracellular
matrixprotein 1(Q16610),secretogranin-2 (P13521),isoform1ofCD166 antigen (Q13740),andinsulin-likegrowth factor bindingprotein
7 (Q16270) can clearly discriminate A-T samples (AT, ∗, 8 samples) from normal controls (0H, x, 5 samples), suggesting that these ﬁve
proteins can potentially serve as a panel of biomarkers of A-T.
the instrument for all samples in this study. The inverse log2
of each sample’s mean was calculated to determine the fold-
change between groups.
2.7. Linear Discriminant Analysis (LDA). LDA was per-
formedusingJMP(version8)toseparatetheA-Tgroupfrom
the control group. The individual protein intensities of 13
Priority 1 proteins that showed signiﬁcant expression
changeswereusedasinputforthisanalysis.Theleastnumber
ofproteinsthat gave the best discrimination between thetwo
groups were selected as biomarker candidates.
2.8. Pathway Analysis. After LDA, a list of ﬁve proteins that
could be used to distinguish A-T from normal samples was
created and analyzed by Pathway Studio (v6.0) (Ariadne,
Rockville, Md, USA) in an attempt to link them with the key
A-T protein ATM. Brieﬂy, the proteins’ corresponding gene
listwasrunagainst theResNetdatabasethatisequippedwith
functional relationships from other scientiﬁc literature and
commercial databases. The ﬁlters that we applied included
“Add shortest path” and “Protein.” Protein interactions and
the biological processes in which they were involved were
noted. The information received was further explored in
the literature to determine the interactions and regulatory
relationships between the proteins of interest and ATM.
2.9. Multiple-Reaction-Monitoring (MRM) Analysis. To ver-
ify and validate the candidate biomarkers of A-T, an MRM-
based targeted proteomic analysis was performed to quantify
the relative protein expression levels between the control
and A-T patient samples. An AB/SCIEX 4000 QTRAP mass
spectrometer interfaced with a Dionex Ultimate 3000 HPLC
system was used for this targeted proteomic quantiﬁcation
study. In this study, ﬁve candidate proteins (listed in Table 4)
were selected for veriﬁcation/validation. The analytes, which
were the same tryptic peptides used for the label-free discov-
ery study, were ﬁrst loaded onto a trapping column (75μm
i.d. × 20mm) and then onto an analytical column (75μm
i.d. × 150mm packed in-house with C18 3μmr e v e r s e d
phase resin), where they were eluted using a gradient of
5–45% acetonitrile with 0.1% formic acid at a ﬂow rate
of 300nL/min over 60min. Source temperature was set at
160◦C, and source voltage was set at 2400V. The collision
energy (CE) for each transition was calculated from the
equations CE = 0.05∗ (m/z) + 8 for (M + 2H+)i o n sa n d
CE = 0.044∗ (m/z) + 8 for (M + 3H+) ions. The declustering
potential (DP) was set at 100V, and a dwell time of 20–30ms
was used to maximize the number of transitions per MRM
experiment. All MRM peptides and transitions are shown in
Table 4. Relative quantiﬁcation was accomplished using the
Analyst software (version 1.5.1 Applied Biosystems).
3.Results
To characterize the alterations in protein expression related
to A-T, we performed LC/MS-based quantitative proteomic
analysis of CSF from control and A-T patients. The patient
informationineachgroupissummarized inTable1.Proteins
identiﬁed based on priority groups are summarized in
Table 2.Atotalof477proteinswere identiﬁedand quantiﬁed
with high conﬁdence in the samples. The expression levels
of 13 proteins from Priority 1 and 7 proteins from Priority
2 were statistically signiﬁcantly changed (listed in Table 3).
The 13 signiﬁcantly changed proteins from the Priority 1
groupwere further analyzed by Linear Discriminant Analysis
(LDA) and pathway analysis for their roles in biological
processes.
Figure 1 illustrates the LDA results. Expression diﬀer-
ences of proenkephalin-A (PENK, P01210), isoform 1 of
extracellular matrix protein 1 (ECM1, Q16610), secreto-
granin-2 (SCG2, P13521), isoform 1 of CD166 antigen
(ALCAM, Q13740), and insulin-like growth factor binding
protein 7 (IGFBP7, Q16270) can clearly discriminate A-T
samples from healthy controls.The literature search results
demonstrate that these ﬁve proteins are involved in either
human cancers or neurodegenerative processes [26–42].
Figure 2 shows a protein-protein interaction network linking
these ﬁve proteins to ATM from the pathway analysis. TheirInternational Journal of Proteomics 5
Table 2: Overall summary of the proteomic analysis.
Protein
priority
Peptide ID
conﬁdence
Multiple
sequences
Number of
proteins
Number of
signiﬁcant
changes
Maximum
absolute
fold-change
Median %CV
(replicate)(a)
Median %CV
(rep + sample)(b)
1H i g h ( >90%) Yes 204 13 1.52 11.97 19.16
2H i g h ( >90%) No 273 7 4.30 36.60 47.06
Overall 477 20 4.30 24.29 33.11
(a)Replicate %CV represents technical variations.
(b)Rep + sample %CV represents overall variations including both technical and biological variations.
CSF1
MMP2
MMP14
HSPG2
ECM1
TFAP2
C
IGFBP7
TNF
PENK
CCL28
SCG2
MAPK1
MAPK3 ATM
IL2
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BCL2
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ALCAM
REL
Figure 2: Pathway analysis linking ﬁve A-T biomarker candidates and ATM. Pathway studio was used to link the A-T biomarker candidates
with ATM. Direct interactions are represented by solid lines, whereas indirect interactions are shown in dashed lines.
relative protein expression levels as determined by MRM are
s h o w ni nF i g u r e3.
For QA/QC purpose, chicken lysozyme was spiked into
every individual sample at a constant amount (10ng chicken
lysozyme/2μg of sample) before tryptic digestion. There
were 9 unique chicken lysozyme peptides being detected
and quantiﬁed. After averaging these peptide concentration
values, a −1.099 fold-change was observed with a q-value of
0.77(77%FDR),suggestingthisobservedsmall changeisnot
statistically signiﬁcant and the data obtained from this study
was reliable.
MRM results demonstrate the same direction of protein
expression changes (up- or downregulation) as compared to
the global discovery study, even though the absolute fold-
c h a n g em a yb es l i g h t l yd i ﬀerent in some cases, likely due to
diﬀerences in the platform used. In this targeted proteomic
study, we were able to detect and quantify four out of the
ﬁve proteins of interest. Unfortunately, we were unable to
conﬁdently detect the MRM peptide “SSPSFSSLHYQDAG-
NYVCETA” from ALCAM due to its low abundance. All of
theMRMpeptidesandtransitions foreachproteinofinterest
are listed in Table 4.6 International Journal of Proteomics
Table 3: Priority 1 and Priority 2 proteins.
Protein name Priority
group
Swiss-Prot
accession number Peptides used for protein identiﬁcation
Peptide ID
conﬁdence
(%)
Fold-Change (negative
values indicate
downregulation)(a)
LVRPADINFLACVMECEGKLPSLK >99.99
AEEDDSLANSSDLLKELLETGDNR >99.99
Proenkephalin-A 1 P01210 ECSQDCATCSYR 93.45 1.29
ELLETGDNR 99.31
ELLQLSKPELPQDGTSTLR 99.23
FSCFQEEAPQPHYQLR >99.99
Isoform 1 of
Extracellular
matrix protein 1
1 Q16610 QHVVYGPWNLPQSSYSHLTR >99.99 1.42
NIWRDPALCCYLSPGDEQVNCFNINYLR >99.99
ACPSHQPDISSGLELPFPPGVPTLDNIK >99.99
IESQTQEEVR >99.99
TNEIVEEQYTPQSLATLESVFQELGK >99.99
VLEYLNQEK >99.99
Secretogranin 2 1 P13521 GQGSSEDDLQEEEQIEQAIK >99.99 1.35
EHLNQGSSQETDKLAPVS >99.99
ALEYIENLR 90.56
QYWDEDLLMK 99.73
Isoform 1 of
CD166 antigen 1 Q13740 SSPSFSSLHYQDAGNYVCETALQEVEGLK >99.99 1.52
ALFLETEQLK 91.12
ITVVDALHEIPVK >99.99
SSSDTCGPCEPASCPPLPPLGCLLGETR >99.99
SRYPVCGSDGTTYPSGCQLR >99.99
Insulin-like growth
factor binding
protein 7
1 Q16270 TELLPGDRDNLAIQTR 99.98 −1.46
EDAGEYECHASNSQGQASASAK 99.99
AGAAAGGPGVSGVCVCK >99.99
GTCEQGPSIVTPPK 99.50
YIPPCLDSELTEFPLR >99.99
SPARC 1 P09486 APLIPMEHCTTR 99.96 −1.47
PPCLDSELTEFPLR 99.52
RLEAGDHPVELLAR >99.99
GRPEAQPPPLSSEHKEPVAGDAVPGPK >99.99
LADLASDLLLQYLLQGGAR >99.99
ESAREEEEAEQER >99.99
NSEPQDEGELFQGVDPR >99.99
RPESALLGGSEAGER >99.99
Neurosecretory
protein VGF 1 O15240 THLGEALAPLSK >99.99 1.42
VGEEDEEAAEAEAEAEEAER >99.99
LLQQGLAQVEAGR >99.99
NAPPEPVPPPR >99.99
GLQEAAEER 95.27
FGEGVSSPK >99.99
AYQGVAAPFPK >99.99International Journal of Proteomics 7
Table 3: Continued.
Protein name Priority
group
Swiss-Prot
accession number Peptides used for protein identiﬁcation
Peptide ID
conﬁdence
(%)
Fold-Change (negative
values indicate
downregulation)(a)
TPP1 1 B5MDC1 YLTLENVADLVRPSPLTLHTVQK 98.74 −1.44
VPIPWVSGTSASTPVFGGILSLINEHR >99.99
GIEDEQDLVPLEVTGVVFHYR >99.99
Neurocan core
protein 1 O14594 RNPQELYDVYCFAR >99.99 1.30
ELGGEVFYVGPAR >99.99
HSGFEDELSEVLENQSSQAELK >99.99
AEGNNQAPGEEEEEEEEATNTHPPASLPSQK >99.99
GEQEHSQQKEEEEEMAVVPQGLFR 99.07
ELQDLALQGAK >99.99
PQALPEPMQESK >99.99
Chromogranin A 1 P10645 SEALAVDGAGKPGAEEAQDPEGK >99.99 1.31
RPEDQELESLSAIEAELEK >99.99
EDSLEAGLPLQVR >99.99
YPGPQAEGDSEGLSQGLVDREK >99.99
SGELEQEEER >99.99
TDGARPQALPEPMQESK >99.99
GLSAEPGWQAK >99.99
AIGAVPLIQGEYMIPCEK >99.99
ISVNNVLPVFDNLMQQK >99.99
FDGILGMAYPR >99.99
Cathepsin D 1 P07339 VSTLPAITLK 98.91 −1.37
TMSEVGGSVEDLIAK >99.99
VGFAEAAR 90.97
LLDIACWIHHK 99.98
VTEIWQEVMQR >99.99
LACCVVGVCGPGLWER >99.99
SOD3 1 P08294 AGLAASLAGPHSIVGR 96.66 −1.37
AVVVHAGEDDLGR >99.99
RDDDGALHAACQVQPSATLDAAQPR >99.99
GGNQASVENGNAGR >99.99
NGVNVISGPIFDYDYDGLHDTEDKIK 99.71
YDAFLVTNMVPMYPAFK >99.99
SYTSCCHDFDELCLK >99.99
NKLDELNKR >99.99
RLHYANNR >99.99
VNSMQTVFVGYGPTFK >99.99
DIEHLTSLDFFR >99.99
ENPP2 1 Q13822 EIDKIVGQLMDGLK >99.99 −1.36
TEFLSNYLTNVDDITLVPGTLGR >99.99
RWHVAR 92.27
SCGTHSPYMRPVYPTK >99.99
SYPEILTLK 94.45
QAEVSSVPDHLTSCVRPDVR 99.79
GESHWVDDDCEEIK >99.99
VMPNIEK 94.62
IEDIHLLVER >99.998 International Journal of Proteomics
Table 3: Continued.
Protein name Priority
group
Swiss-Prot
accession number Peptides used for protein identiﬁcation
Peptide ID
conﬁdence
(%)
Fold-Change (negative
values indicate
downregulation)(a)
VSPSFSQNCLAYK 99.85
KPDQHFKPYLK 99.79
PAVLYR 91.70
PAGFVRPPLIIFSVDGFR >99.99
CFFQGDHGFDNK 90.16
QMSYGFLFPPYLSSSPEAK 99.03
Insulin-like growth
factor binding
protein complex
acid abile chain
2 P35858 LAYLQPALFSGLAELR >99.99 −1.45
Caspase
recruitment
domain-containing
protein 14
2 Q9BXL6 GALPGAK 95.91 −1.95
Endothelial
cell-selective
adhesion molecule
2 Q96AP7 QLPSFQTFFAPALDVIR 99.94 1.95
Isoform 1 of phos-
phatidylinositol
3-kinase regulatory
subunit gamma
2 Q92569 LGEIHDSK 90.36 −2.16
Neutral amino acid
transporter B 2 Q15758 SCTVLNVEGDALGAGLLQNYVDR 90.14 −1.87
Isoform 1 of
latrophilin-1 2 O94910 TDDKICDADPFQMENVQCYLPDAFK >99.99 1.57
Isoform 1 of
histone-lysine N-
methyltransferase
MLL3
2 Q8NEZ4 IQPPIAQLPIK 91.36 2.03
(a)The fold-changes are the average values from all the peptides used for protein quantiﬁcation; individual values from individual peptide are given in the
supplementary data.
4.Discussion
Much of the eﬀort in proteomics has been devoted to
improve the sensitivity of the instrument and measurement
accuracy. At the present time, there is no consensus within
the ﬁeld of proteomics on any one technology that can attain
complete and quantitative protein coverage of all proteins
in a given tissue or bioﬂuid. The most commonly used
proteomic approach, the so called “bottom-up” approach,
utilizes a two-step approach: peptide separation followed
by peptide/protein identiﬁcation and quantiﬁcation by mass
spectrometry (MS). Two-dimensional gel electrophoresis
(2DE) has been the workhorse for protein separation in pro-
teomics research eﬀorts in the past decade, but its inability
to widen the protein dynamic range and its low throughput
remain its biggest disadvantages and thus limit its utility in
large-scale and highthroughput proteomic analysis.
One alternative approach to 2DE is the nongel-based liq-
uid chromatography mass spectrometry-based shotgun pro-
teomic technology [43–46]. It provides a powerful analytical
platform to resolve and identify thousands of proteins from
a complex biological sample in a single experiment. This
approach is rapid and more sensitive, and it increases
the protein dynamic range 3- to 4-fold as compared to
2DE. The hallmark of this method is its ability for high-
throughputlarge-scale proteomicanalysis [47,48].Although
some success using isotopic labeling technology in combi-
nation with mass spectrometry for protein quantiﬁcation
has been reported [48], recently developed label-free protein
quantiﬁcation technology [14] has become a major platform
for biomarker discovery primarily due to the high costs of
the labeling reagents, especially for a large-scale study. In
this study, we used a peak-intensity-based label-free protein
quantiﬁcation method that was previously applied for many
other studies [14, 15, 17, 18].
One challenge to studying the neurodegenerationseen in
A-Tisaccesstoaﬀectedbraintissue.Forthisreason,wechose
CSF to analyze since this bioﬂuid is in direct contact with
the brain and studies of other neurodegenerative diseases
have shown that disease-speciﬁc changes in the brain can beInternational Journal of Proteomics 9
Table 4: MRM transitions for biomarker candidates.
Protein name Swiss-Protaccession
number
Peptides used for MRM
validation assay MRM transitions Observed
fold-change
1063.7 (M + 2H+) → 634.4 (y6)
Proenkephalin-A P01210 ELLQLSKPELPQDGTSTLR 1063.7 (M + 2H+) → 974.5 (y9) 2.57
1063.7 (M + 2H+) → 1313.7 (y12)
Isoform 1 of
Extracellular matrix
protein 1 (ECM)
790.9 (M + 3H+) → 588.3 (y10)
Q16610 QHVVYGPWNLPQSSYSHLTR 790.9 (M + 3H+) → 871.9 (y15) 1.19
790.9 (M + 3H+) → 953.5 (y16)
610.1 (M + 2H+) → 488.7 (y82+)
Secretogranin 2 P13521 IESQTQEEVR 610.1 (M + 2H+) → 976.5 (y8) 1.54
VLEYLNQEK 568.6 (M + 2H+) → 794.4 (y6)
568.6 (M + 2H+) → 923.4 (y7)
478.9 (M + 3H+) → 560.8 (y102+)
ITVVDALHEIPVK 478.9 (M + 3H+) → 610.4 (y112+) −3.38
478.9 (M + 3H+) → 660.9 (y122+)
Insulin-like growth
factor binding protein
7( I G F B P 7 )
Q16270 AGAAAGGPGVSGVCVCK 746.9 (M + 2H+) → 783.4 (y7)
746.9 (M + 2H+) → 1036.5 (y10)
746.9 (M + 2H+) → 1150.6 (y12)
Isoform 1 of CD166
antigen Q13740 SSPSFSSLHYQDAGNYVCETA Failed to detect this peptide N/A
detected [20–22]. A recent study by Cheema et al. [49], using
analysis of ATM-mediated gene and protein expression in
A-T ﬁbroblasts found a completely diﬀerent set of proteins
than those observed in our CSF study and highlights
the importance of selecting a clinically relevant tissue for
biomarker discovery.
4.1. Conﬁdence in the Methodology. In this proteomic study,
we did not detect A-T-related proteins, such as ATM-related
protein kinases or their substrates [7]. This could be due
to the inability of current LC/MS technology to conﬁdently
detect low-abundance proteins. However, the advantages of
the method far outweigh this limitation. Firstly, proteomic
analysis ignores transcripts that may never be translated by
detecting only the end products of gene activity, giving it
an advantage over genomic analysis. Secondly, the LC/MS-
based label-free protein quantiﬁcation technology used here
has proven itself a powerful tool to resolve and identify
thousands of proteins from complex biological samples [16,
50]. It is a method that compares the relative expression
levels of the same protein under diﬀerent physiological
conditions. The method is rapid highthroughput, and more
sensitive than many other proteomic platforms [16], and it
increasestheproteindynamic range3- to4-fold comparedto
the conventional 2D gel-based proteomic platform. During
the development of the method, chicken lysozyme was
used for QA/QC purposes, and the method has since
been robustly tested on many diﬀerent types of samples
[15–18]. Automation allows it to be applied to large-scale
proteomic analysis; thus, it has become a tool of choice for
biomarker discovery [15, 51]. The inclusion of statistics in
both the experimental design and data analysis allows for
the detection of small but statistically signiﬁcant changes
not oﬀered by other methods. We are, therefore, conﬁdent
in the qualitative and quantitative data produced by this
method.
4.2. Signiﬁcance of Results
A. Statistical Motivation. The size of the treatment or disease
eﬀect (signal) needs to be evaluated relative to the sample
and replicate variation (noise). The signal to noise ratio
is estimated based on a statistical model. If the data have
multiple sources of random variation such as biological
samples and replicates then the data are modeled as a Linear
Mixed Model (A generalization of an ANOVA, Analysis
of Variance). This kind of model, especially when applied
to complex experimental designs, cannot be handled by
introductory methods such as t-tests. The exact scale of the
protein expression used in the model can make a diﬀerence
in the sensitivity. There is usually a large technical variation
introduced by the act of “measurement” in any “omics”
study. Randomization of measurement order will eliminate
the bias, but it is still extremely important to “normalize”
or mathematically calibrate the measurement. This is a
highly technical matter but can be viewed as similar to
mathematically resetting a scale to zero before each measure-
ment. We use a statistically based method called “quantile10 International Journal of Proteomics
ECM 25
20
15
10
5
0
NC AT
×103
(a)
IGFBP7 30
25
20
15
10
5
0
×104
NC AT
(b)
10
8
6
4
2
0
×104
NC AT
Proenkephalin-A
(c)
25
20
15
10
5
0
NC AT
×103
Secretogranin-2
(d)
Figure 3: MRM analysis of A-T biomarker candidates. Relative protein expression levels were determined by averaging the area-under-the-
Curve (AUC) for each selected MRM transition for each peptide shown in Table 4. For secretogranin-2 and IGFBP7, the fold-changes from
both MRM peptides were also averaged. Statistical analysiswas performed by ANOVA models using PROC MIXED in SAS. P<. 05.
normalization” [25] which was the result of considerable
research on genomic data. Because “omics” measures of
expression are usually on an arbitrary scale, it is best to
evaluateratiosortheirequivalentdiﬀerencesonthelogscale.
Logbase 2 is chosen because a unit diﬀerenceon the logscale
is equivalent to a two-fold change.
B. Five Biomarker Candidate Proteins. From the LDA, ﬁve
candidate proteins whose relative expression levels could be
used to precisely discriminate control samples from A-T
patient samples were discovered. After reviewing the litera-
ture, all of these proteins were found to play some role in
either cancer or neurodegenerative processes, or both, which
lends support to these proteins being viable biomarkers of
A-T.
T h eﬁ r s to ft h e s eﬁ v ep r o t e i n si sp r o e n k e p h a l i n - A
(PENK), which is an opioid neuropeptide precursor, a neu-
roendocrine hormone, and a cytokine. It is involved in pain
perception, modulation of the immune system, anticonvul-
sant activity, and the neurodegenerative disorder Hunting-
ton’s disease [27, 30]. It is also involved in several cancers,
including breast cancer and prolactin-secreting pituitary
adenoma [26, 28, 29]. This protein was found 30% overex-
pressed in A-T samples.
Isoform 1 of Extracellular matrix protein 1 (ECM1),
which is 42% over-expressed in A-T samples, is involved in
many cancers, including breast, esophageal, laryngeal, thy-
roid, and lung cancers and may play a role in angiogenesis
[31]. It is mutated in lipoid proteinosis, a dermatolog-
ical disease in which patients may develop neurologicalInternational Journal of Proteomics 11
abnormalities such as temporal lobe epilepsy and mental
retardation [32].
The third protein, the neuroendocrine prohormone
secretogranin 2 (SCG2), has a role in both neurological pro-
cesses and cancer. SCG2 is over-expressed by 35% in the A-T
patients and is involved with the packaging and sorting of
peptide hormones and neuropeptides into secretory vesicles.
One of its gene products promotes neuroprotection and
neuronal plasticity in mice and humans [38]. Secretogranin
2 has also been suggested to be involved in neuroendocrine
tumors and amyotrophic lateral sclerosis (a neurodegenera-
tive disorder) [39, 40].
The fourth protein, isoform 1 of CD166 antigen
(ALCAM), which has a role in cancer and neurological dis-
orders [33–37], was found to be 52% over-expressed in the
A-Tsamples. Itisinvolvedinneuriteextension byneuronsin
chickens[35]andintheneurodegenerativedisordermultiple
sclerosis [34]. In addition, CD166 plays a role in many
cancers, including melanoma, prostate, colorectal, pancreas,
and breast [33, 36, 37].
The ﬁnal protein, insulin-like growth factor binding pro-
tein 7 (IGFBP7), is downregulated 46% in A-T compared to
control samples. It plays a role in regulating proliferation,
diﬀerentiation, and apoptosis. Additionally, it is involved in
several types of cancers, including colorectal and inﬂamma-
tory breast cancers [41, 42].
C. Other Priority 1 Proteins. The remaining eight signiﬁ-
cantly changed proteins in the Priority group 1 are SPARC
(secreted protein acidic and rich in cysteine), neurosecretory
protein VGF, TPP1 (cDNA FLJ56402, highly similar to
tripeptidyl-peptidase 1), neurocan core protein, chromo-
granin A, cathepsin D, SOD3 (extracellular superoxide dis-
mutase),and ENPP2 (isoform1 ofectonucleotidepyrophos-
phatase/phosphodiesterase family member 2) (Table 3).
Among these proteins, SPARC, neurosecretory protein VGF,
TPP1, and SOD3 are of particular interest because they have
been implicated in neurodegenerative processes.
SPARC is a unique matricellular glycoprotein involved
in many types of diseases including cancer, inﬂammation,
and neurodegeneration [52–54] .I t sf u n c t i o ni sa s s o c i a t e d
with cell development, remodeling, cell turnover, and tissue
repair. Our observed downregulation (1.47-fold) of this
protein in A-T patients implicates deﬁciencies associated
with these cellular functions in this disease.
Neurosecretory protein VGF has been identiﬁed by many
proteomic studies [55–57]. It plays a role in neuronal
communication [56]. This gene is speciﬁcally expressed in
a subpopulation of neuroendocrine cells and is upregulated
by nerve growth factor [57]. However, its exact function
remains to be discovered.
TPP1 (cDNA FLJ56402, highly similar to tripeptidyl-
peptidase 1), also known as CLN2, is a member of the
family of serine-carboxyl proteinases and plays a crucial
role in lysosomal protein degradation; a deﬁciency in this
enzyme leads to fatal neurodegenerative disease [58]. It
is also involved in telomere protection [59]. Based on its
known functions, TPP1 is expected to be down-regulated in
A-T patients, which is what we observed (down-regulated
1.44-fold).
SOD3 is an antioxidant enzyme associated with many
pathways and diseases. Its association with neurodegenera-
tion has been reported previously in a study of antioxidant
gene therapy [60]. SOD3’sfunction is to protect against neu-
rodegeneration. Down-regulation (1.37-fold) of this protein
in A-T patients would suggest less of a protective eﬀect by
SOD3. Importantly, a large body of evidence suggests that
oxidative stress plays some role in the pathophysiology of
A-T. As a recent example, one group has shown that ATM
can be directly activated by oxidation in the absence of DNA
double-strand breaks, implying that ATM may act as a redox
sensor capable of regulating cellular responses to oxidative
stress as well as genotoxic stress [61].
5.Conclusion
We identiﬁed novel CSF biomarker candidates for A-T from
the 13 priority 1 proteins with signiﬁcant absolute fold-
changes of at least 1.3 (30% increase or decrease) (q<
0.05). LDA was applied to assess the ability of individual
and/or combinations of these proteins to correctly classify
individuals into the control or disease group. The selectivity
and speciﬁcity from the LDA was high, suggesting that
it is possible to correctly assign individuals to the proper
group (control or A-T patient) when the expression levels
of these biomarker candidates are accurately measured in
the CSF. Findings from our study conﬁrm that the mass
spectrometry-based label-free protein quantiﬁcation and
MRM technologies can be used successfully for biomarker
discovery and validation. However, limitations of our study
require us to interpret the data with caution. First, the
current study constituted a small sample size, and further
validation studies with a larger set of patient cohort samples
are necessary. Second, the fold-changes observed in the
study are relatively small, which require high measurement
precision to produce high quality, clinically valid data. Thus,
mass spectrometry-based methods may not be a practical
approach for clinical applications. Third, CSF may not
be an ideal biospecimens for prognostic applications due
to the invasiveness involved in sample collection. Future
studies involving serum or plasma samples would make
this biomarker discovery strategy even more attractive
with the hope that such noninvasive biospecimens can be
incorporated into routine clinical practice and utilized in
clinical trials for the assessment of potential therapeutic
compounds.
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